Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure

Completed · Phase 4

Conditions studied: Kidney Transplant

In brief

A study to determine the effect on renal function in renal transplant patients with biopsy proven Chronic allograft nephropathy (CAN) nephropathy who are switched from a Calcinerin inhibitor (CI) triple drug regimen to a Rapamycin based triple drug regimen or maintained on their CI protocol

Key facts

Study ID

NCT00223678

Run by

Vanderbilt University Medical Center

People needed

20

Starts

2000-06-01

Expected to finish

2009-10-01

Last updated by the study team

2017-06-21

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is the recipient of a cadaveric or living donor renal transplant.
• Patient was > 12 years of age at the time of transplant.
• Patient is at least 3 months post-transplant.
• Patient has been on a calcineurin inhibitor based immunosuppression since the transplant.
• Patient has one of the following risk factors for chronic renal allograft failure:
• I. Serum creatinine > 2.0 mg/dL 3 months or later post-transplant in males patients.
• II. Serum creatinine > 1.7 mg/dL 3 months or later post-transplant in female patients.
• III. Serum > 30% increased over post discharge nadir.
• Patients had a renal biopsy that shows chronic allograft nephropathy.
• Patient or legal guardian had signed and dated an Institutional Review Board (IRB) approved informed consent document and is willing and able to follow study procedures.
• If female and of child bearing potential, patient has a negative pregnancy test and agrees to practice effective birth control while receiving mycophenolate mofetil (MMF), Rapamycin and other immunosuppressants.

You may not qualify if…

• Patient is the recipient of a solid organ transplant other than the kidney.
• Patient is dialysis dependent.
• Patient has recurrence of primary renal disease, or de novo renal disease.
• Patient has an estimated creatinine clearance <25ml/min calculated using the Cockcroft/Gault formula.
• Patient has changed maintenance immunosuppressant therapy (e.g., azathioprine to MMF) within three months of randomization.
• Baseline biopsy shows acute rejection Banff Grade > Class 2 (IIB).
• Patient required anti-lymphocyte therapy to treat rejection found on baseline biopsy.
• Patient has received an investigational immunosuppressant within three months.
• Patient is pregnant or lactating.
• Patient is a known carrier of any of the HIV viruses.
• Patient has known hypersensitivity to Rapamycin, or any of the excipients of the drug.

Where it is running

• Vanderbilt University — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.